ArticleBMC cancer2022

Real-world efficiency of lenvatinib plus PD-1 blockades in advanced hepatocellular carcinoma: an exploration for expanded indications.

Xuqi Sun et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.